| ||
| Synta Announces Ganetespib Phase 2 Non-small Cell Lung Cancer Tr ... The five year survival rate for advanced-staged lung cancer is less than 5%. Approximately 85% of all lung cancers are classified as non-small cell. ... www.biotech-finances.com/en/cp-137799.html |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment